Convergen

Convergen develops targeted protein degradation therapies for diseases associated with pathological protein aggregates.

Health and bioManufacturing and industrial

Convergen has no funding amount on record yet; its latest known round is Seed (Aug 2026). Recent Funding first saw it on October 2, 2026.

Founders and team

• JS
  Jinquan Sun Founder

  source: crunchbase.com

Raise history

1. August 31, 2026
   Seed · amount undisclosed
   Source: crunchbase.com

Related bio health companies

• MM-BasedOct 1, 2026
• AAyna HealthOct 1, 2026
• VVytalYou$830K · Sep 30, 2026
• LLindera USSep 29, 2026
• OOrtet$500M · Sep 29, 2026
• AAptadir Therapeutics$45M · Sep 29, 2026
• GGoerSep 29, 2026
• FFreyyaSep 29, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/convergen.